

10-14-1999

FORM PTO-1595
1-31-92U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

HEET

Docket No. 245/253

101170781

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): <u>mls</u> <u>10.12.99</u> Innovir Laboratories, Inc. Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name and address of receiving party: Name: <u>Ribozyme Pharmaceuticals, Inc.</u> Street Address: <u>2950 Wilderness Place</u> City: <u>Boulder</u> State: <u>CO</u> Zip: <u>80301</u>
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other Execution Date: <u>9 August 1999</u>	Additional name(s) & address(es) attached? <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No Name: <u>Innovir Laboratories, Inc.</u> Street Address: <u>2751 Centerville Road, Suite 210</u> City: <u>Little Falls II Wilmington</u> State: <u>DE</u> Zip: <u>19808</u>
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No(s). B. Patent No(s): <u>(5,741,679)</u> Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Richard J. Warburg</u> Internal Address: <u>LYON & LYON LLP</u> <u>633 West Fifth Street, Suite 4700</u> <u>Los Angeles, CA 90071-2066</u>	6. Total number of applications and patents involved: <u>1</u> 7. Total fee (37 CFR 3.41): \$ <u>40.00</u> <input checked="" type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Charge this Deposit Account if any additional fee is required 8. Deposit Account Number: <u>12-2475</u>

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.
Wesley B. Ames Date: 8 October 1999
Wesley B. Ames, Reg. No. 40,893

Total number of pages including cover sheet: 3

OMB No. 0651-0011 (exp. 4/94)

Do not detach this portion

Mail documents to be recorded with required cover sheet information to:

Commissioner of Patents and Trademarks

Box Assignments

Washington, D.C. 20231

10/14/1999 DNGUYEN 00000018 5741679

01 FC:581

40.00 00

Public burden reporting for this sample cover sheet is estimated to average about 30 minutes per document to be recorded, including time for reviewing the document and gathering the data needed, and completing and reviewing the sample cover sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Office of Information Systems, PK2-1000C, Washington, D.C. 20231, and to the Office of Management and Budget, Paperwork Reduction Project, (0651-0011), Washington, D.C. 20503

SD-130085.1

PATENT
REEL: 010299 FRAME: 0106

ASSIGNMENT

Innovir Laboratories, Inc., a corporation of the State of Delaware, having its principal place of business at 2751 Centerville Road, Suite 210, Little Falls II, Wilmington, Delaware 19808, in consideration of ten dollars and other valuable consideration paid to it by Ribozyme Pharmaceuticals, Inc., a corporation of the State of Delaware, having its principal place of business at 2950 Wilderness Place, Boulder, Colorado 80301, and Innovir Laboratories, Inc., a corporation of the State of Delaware, having its principal place of business at 2751 Centerville Road, Suite 210, Little Falls II, Wilmington, Delaware 19808, the receipt of which is hereby acknowledged, does hereby sell, assign and transfer a joint and undivided interest to said Ribozyme Pharmaceuticals, Inc. and Innovir Laboratories, Inc., their successors and assigns, the entire interest for the United States of America, and its territories and all foreign countries and jurisdictions, including all rights of priority under the International Convention for the Protection of Industrial Property, in a certain invention or improvement in "*Regulatable Nucleic Acid Therapeutic and Methods of Use Thereof*" described in U.S. Application Serial No. 08/307,401 filed in the United States Patent and Trademark Office on September 16, 1994, by Shaji T. George, Andy Shih, and Jeffrey Michael Bockman, which issued April 21, 1998, as U.S. Patent No. 5,741,679; which is a continuation of and claims priority to U.S. Application Serial No. 07/987,465 filed December 4, 1992, now abandoned, in the United States Patent and Trademark Office, and in all Letters Patent of the United States and its territories and all foreign countries and jurisdictions which may or shall be granted on said listed invention, or any parts thereof, or on said application, or any provisional, divisional, continuation, continuation-in-part, reissue, or other applications based in whole or in part thereon, and including the right to pursue and recover past damages for infringement thereof. And Innovir Laboratories, Inc. agrees, for itself and its successors and assigns, with said corporations and their successors and assigns, but at their expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent, and to recover for patent infringement of the Patent, in the United States and its territories and in all other foreign countries and jurisdictions to said corporations, with specifications and claims in such form as shall be approved by the counsel of said corporations, and to vest and confirm in said corporations, their successors and assigns, the legal title to all such patents.

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporations, their successors and assigns.

WITNESS my hand and seal this 9th day of AUGUST, 1999.

INNOVIR LABORATORIES, INC.

David A. Jackson

By (name): DAVID A. JACKSON

Title: CHAIRMAN

State of Delaware)

County of New Castle)

Then personally appeared the above named David A. Jackson, agent empowered to act on behalf of assignor Innovir Laboratories, Inc., and acknowledged the foregoing instrument to be his/her free act and deed, before me this 9th day of August, 1999.

Suzanne L. Deen

Notary Public

My Commission expires: 3/7/2001